Amyris Inc. (AMRSQ)
| Market Cap | 1.48M |
| Revenue (ttm) | 268.22M +20.5% |
| Net Income | -614.55M |
| EPS | -1.92 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,302 |
| Open | 0.0020 |
| Previous Close | 0.0020 |
| Day's Range | 0.0020 - 0.0020 |
| 52-Week Range | n/a |
| Beta | 1.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AMRSQ
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripe... [Read more]
News
Amyris Takes Full Ownership of Brazilian Industrial Fermentation Plant and Invests in Completion of Fourth Precision Fermentation Line
EMERYVILLE, Calif. , May 29, 2025 /PRNewswire/ -- Amyris, Inc., a vertically integrated synthetic biology company and leading innovator in the field of industrial biotechnology, today announced that i...
Retail investors flock to penny stocks WeWork, Amyris, Proterra
WeWork, a prized startup just four years ago but now a micro-cap, and other penny stocks such as Amyris and Proterra are the latest focus of speculative bets from retail traders, with shares of the fi...
Biotech Company Amyris Files for Bankruptcy
Synthetic biotechnology company Amyris filed for Chapter 11 bankruptcy protection as it restructures, leading its share price to drop more than 70% in early trading Thursday.
AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION
Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif...
AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE
EMERYVILLE, Calif. , June 26, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
AMYRIS INITIATES STRATEGIC TRANSFORMATION PROGRAM AND SECURES FUNDING
EMERYVILLE, Calif. , June 5, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...
AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE
EMERYVILLE, Calif. , May 19, 2023 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ techn...
AMYRIS, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
Core revenue of $56.1 million exceeded Q1 guidance of $49.9 million Cash operating expense down 4% compared to Q1 2022 and down 24% versus Q4 2022 Completed strategic partnership with Givaudan on Apri...
AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9
EMERYVILLE, Calif. , May 2, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-t...
AMYRIS REPORTS Q1 2023 REVENUE
EMERYVILLE, Calif. , April 24, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its La...
AMYRIS CLOSES STRATEGIC TRANSACTION WITH GIVAUDAN
Leveraging Amyris' industry-leading biotechnology platform in Beauty for the development and supply of clean sustainable ingredients EMERYVILLE, Calif. , April 5, 2023 /PRNewswire/ -- Amyris, Inc. (Na...
AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior year Full year Consumer revenue...
AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023
EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
GIVAUDAN TO ACQUIRE PORTFOLIO OF MAJOR COSMETIC INGREDIENTS FROM AMYRIS AND TO ESTABLISH STRATEGIC PARTNERSHIP FOR NATURAL, SUSTAINABLY SOURCED INGREDIENTS FOR THE BEAUTY INDUSTRY
The bio-based sustainable blockbuster ingredients Squalane, Hemisqualane and Cleanscreen as well as development of future cosmetic ingredients from Amyris will accelerate both companies' leadership in...
AMYRIS LAUNCHES 4U BY TIA™ HAIRCARE LINE EXCLUSIVELY AT WALMART
EMERYVILLE, Calif. , Jan. 30, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
AMYRIS TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE
EMERYVILLE, Calif. , Jan. 4, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...
AMYRIS ANNOUNCES $50 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT
EMERYVILLE, Calif. , Dec. 29, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
AMYRIS SUCCESSFULLY ADVANCES STRATEGIC TRANSACTION
EMERYVILLE, Calif., Dec. 27, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...
AMYRIS CONSUMER BRANDS DELIVER 80% CYBER MONDAY LIKE-FOR-LIKE GROWTH
EMERYVILLE, Calif. , Nov. 30, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
AMYRIS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
Sixth consecutive quarter of record consumer revenue – Consumer revenue of $46.6 million increased 98% compared to Q3 2021 Record core revenue of $71.1 million grew 49% compared to the prior year quar...
AMYRIS TO HOST THIRD QUARTER 2022 FINANCIAL RESULTS CONFERENCE CALL ON NOVEMBER 8
EMERYVILLE, Calif. , Nov. 1, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...
Amyris and World Wildlife Fund Announce Partnership to Protect Biodiversity
EMERYVILLE, Calif. , Oct. 25, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
AMYRIS SUCCESSFULLY LAUNCHES TWO NEW CONSUMER BRANDS
EMERYVILLE, Calif. , Oct. 24, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
Amyris Brands Expanding in UK and Europe. Executing on continued accelerated growth and lower costs
EMERYVILLE, Calif. , Oct. 11, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
AMYRIS TO PARTICIPATE AT SEPTEMBER INVESTOR CONFERENCES
EMERYVILLE, Calif. , Sept. 7, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...